Stock data
4D Molecular Therapeutics, Inc. (FDMT)
4D Molecular Therapeutics, Inc. (FDMT) reported revenue of US$85.21M and net income of -US$140.11M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$85.21M | — | -US$159.55M | -US$140.11M | — |
| 2024 | US$0.04M | — | -US$187.84M | -US$160.87M | — |
| 2023 | US$20.72M | — | -US$112.87M | -US$100.84M | — |
| 2022 | US$3.13M | — | -US$110.03M | -US$107.49M | — |
| 2021 | US$18.04M | — | -US$71.33M | -US$71.32M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$3.78M | -US$72.94M | — |
| 2026-03-31 | US$3.05M | -US$68.76M | — |
| 2025-12-31 | US$85.09M | US$19.40M | — |
| 2025-09-30 | US$0.09M | -US$56.88M | — |
| 2025-06-30 | US$0.01M | -US$54.66M | — |
| 2025-03-31 | US$0.01M | -US$47.97M | — |
| 2024-12-31 | US$0.00M | -US$49.67M | — |
| 2024-09-30 | US$0.00M | -US$43.84M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.